bemarituzumab + pembrolizumab + carboplatin + nab-paclitaxel

This therapy is a four-drug combination regimen comprising **bemarituzumab** (an anti-FGFR2b monoclonal antibody), **pembrolizumab** (a PD-1 immune checkpoint inhibitor), **carboplatin** (a platinum-based alkylating chemotherapeutic), and **nab-paclitaxel** (albumin-bound paclitaxel, a taxane chemotherapeutic agent). - **Bemarituzumab** targets the fibroblast growth factor receptor 2b (FGFR2b), inhibiting FGFR2b-mediated signaling and tumor proliferation. - **Pembrolizumab** works by blocking programmed death-1 (PD-1), thereby promoting T-cell mediated immune responses against tumors. - **Carboplatin** induces DNA crosslinking and apoptosis in rapidly dividing tumor cells. - **Nab-paclitaxel** stabilizes microtubules, inhibiting mitosis and cell division. This combination has been explored in clinical trials for advanced solid tumors, especially **locally advanced/metastatic gastric and gastroesophageal junction cancers**, and also in non-small cell lung cancer (NSCLC). The overall rationale is to synergistically combine targeted therapy (bemarituzumab), immunotherapy (pembrolizumab), and chemotherapy (carboplatin and nab-paclitaxel) to maximize antitumor efficacy, especially in patients with FGFR2b overexpression.